{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:37:17Z","timestamp":1787647037901,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005200","name":"New Jersey Commission on Spinal Cord Research","doi-asserted-by":"publisher","award":["CSCR23IRG005"],"award-info":[{"award-number":["CSCR23IRG005"]}],"id":[{"id":"10.13039\/100005200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001774","name":"New Jersey Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 GM135141"],"award-info":[{"award-number":["T32 GM135141"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R00HL148646-01"],"award-info":[{"award-number":["R00HL148646-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["PC 140-24"],"award-info":[{"award-number":["PC 140-24"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.rpth.2024.102614","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:26:55Z","timestamp":1730305615000},"page":"102614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dependence of clot structure and fibrinolysis on apixaban and clotting activator"],"prefix":"10.1016","volume":"8","author":[{"given":"Rebecca A.","family":"Risman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitali","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Tutwiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102614_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/rth2.12191","article-title":"Fibrinogen and fibrin: an illustrated review","volume":"3","author":"Pieters","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102614_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/978-3-319-49674-0_13","article-title":"Fibrin formation, structure and properties","volume":"82","author":"Weisel","year":"2017","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.rpth.2024.102614_bib3","article-title":"Biomechanics, energetics, and structural basis of rupture of fibrin networks","volume":"12","author":"Ramanujam","year":"2023","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.rpth.2024.102614_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.actbio.2022.12.028","article-title":"Fracture toughness of fibrin gels as a function of protein volume fraction: mechanical origins","volume":"159","author":"Garyfallogiannis","year":"2023","journal-title":"Acta Biomater"},{"key":"10.1016\/j.rpth.2024.102614_bib5","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1039\/D4SM00042K","article-title":"Mechanics and microstructure of blood plasma clots in shear driven rupture","volume":"20","author":"Ramanujam","year":"2024","journal-title":"Soft Matter"},{"key":"10.1016\/j.rpth.2024.102614_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100081","article-title":"Fibrinolysis: an illustrated review","volume":"7","author":"Risman","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102614_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4103\/0019-5049.144643","article-title":"Overview of the coagulation system","volume":"58","author":"Palta","year":"2014","journal-title":"Indian J Anaesth"},{"key":"10.1016\/j.rpth.2024.102614_bib8","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/ATVBAHA.107.141911","article-title":"Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis","volume":"27","author":"Mackman","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2024.102614_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.ATV.0000046238.23903.FC","article-title":"The dynamics of thrombin formation","volume":"23","author":"Mann","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2024.102614_bib10","first-page":"CD008980","article-title":"Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation","volume":"3","author":"Bruins Slot","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rpth.2024.102614_bib11","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCRESAHA.112.276741","article-title":"Oral direct factor Xa inhibitors","volume":"111","author":"Yeh","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.rpth.2024.102614_bib12","doi-asserted-by":"crossref","first-page":"12343","DOI":"10.1074\/jbc.M708843200","article-title":"Factor Xa active site substrate specificity with substrate phage display and computational molecular modeling","volume":"283","author":"Hsu","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.rpth.2024.102614_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/00365513.2024.2369993","article-title":"Effects of dabigatran, rivaroxaban, and apixaban on fibrin network permeability, thrombin generation, and fibrinolysis","volume":"84","author":"Taune","year":"2024","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.rpth.2024.102614_bib14","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/rth2.12443","article-title":"Effect of anticoagulants on fibrin clot structure: a comparison between vitamin K antagonists and factor Xa inhibitors","volume":"4","author":"Gauer","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102614_bib15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2141.2010.08546.x","article-title":"Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate","volume":"152","author":"Blomb\u00e4ck","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102614_bib16","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1111\/jth.14281","article-title":"Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity","volume":"16","author":"Carter","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102614_bib17","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/europace\/euz176","article-title":"Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation","volume":"21","author":"Spinthakis","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.rpth.2024.102614_bib18","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtha.2024.03.011","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial","volume":"22","author":"McBane","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102614_bib19","series-title":"Apixaban. Treasure Island, FL","author":"Agrawal","year":"2024"},{"key":"10.1016\/j.rpth.2024.102614_bib20","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2012-09-306639","article-title":"Mechanisms of fibrin polymerization and clinical implications","volume":"121","author":"Weisel","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102614_bib21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1161\/ATVBAHA.119.313626","article-title":"Effects of post-translational modifications of fibrinogen on clot formation, clot structure, and fibrinolysis: a systematic review","volume":"40","author":"de Vries","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2024.102614_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.blre.2006.11.001","article-title":"Thrombin generation and fibrin clot structure","volume":"21","author":"Wolberg","year":"2007","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2024.102614_bib23","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4645137","article-title":"Clot structure and fibrinolysis in thrombosis and hemostasis","volume":"2017","author":"Bagoly","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.rpth.2024.102614_bib24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/cvr\/cvad017","article-title":"Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice","volume":"119","author":"Z\u0105bczyk","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.rpth.2024.102614_bib25","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1161\/ATVBAHA.111.230631","article-title":"Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases","volume":"31","author":"Undas","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2024.102614_bib26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0037-1615843","article-title":"Structural studies of fibrinolysis by electron and light microscopy","volume":"82","author":"Weisel","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102614_bib27","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/01.ATV.20.5.1354","article-title":"Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy","volume":"20","author":"Collet","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2024.102614_bib28","doi-asserted-by":"crossref","first-page":"21331","DOI":"10.1074\/jbc.M212734200","article-title":"Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots","volume":"278","author":"Collet","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.rpth.2024.102614_bib29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/07853890600852898","article-title":"Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?","volume":"38","author":"Bouma","year":"2006","journal-title":"Ann Med"},{"key":"10.1016\/j.rpth.2024.102614_bib30","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/TA.0000000000003911","article-title":"Elucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: the role of thrombin-activatable fibrinolysis inhibitor","volume":"94","author":"Coleman","year":"2023","journal-title":"J\u00a0Trauma Acute Care Surg"},{"key":"10.1016\/j.rpth.2024.102614_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037802","article-title":"A\u00a0challenging issue in COVID-19 infection: the relationship between PA1-1 and TAFI levels in patients with coagulation disorder: a retrospective and observational study","volume":"103","author":"Altin","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rpth.2024.102614_bib32","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00404-022-06632-y","article-title":"Association between TAFI and PAI-1 polymorphisms with biochemical and hemostatic parameters in polycystic ovary syndrome","volume":"307","author":"Albuquerque","year":"2023","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.rpth.2024.102614_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30959","article-title":"Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity","volume":"71","author":"Hamdy","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.rpth.2024.102614_bib34","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.jtha.2024.04.006","article-title":"RNA therapeutics to control fibrinolysis: review on applications in biology and medicine","volume":"22","author":"Ferraresso","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102614_bib35","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.thromres.2012.07.010","article-title":"Is there any need for a TAFI(a) inhibitor as thrombolytic drug?","volume":"130","author":"Vercauteren","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102614_bib36","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/j.thromres.2012.06.018","article-title":"Intravenous and oral administrations of DD2 [7-Amino-2-(sulfanylmethyl)heptanoic acid] produce thrombolysis through inhibition of plasma TAFIa in rats with tissue factor-induced microthrombosis","volume":"130","author":"Sasaki","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102614_bib37","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2024.102614_bib38","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1681\/ASN.V1261255","article-title":"Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis","volume":"12","author":"Segarra","year":"2001","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rpth.2024.102614_bib39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-0039-1698460","article-title":"Interpretation and validation of maximum absorbance data obtained from turbidimetry analysis of plasma clots","volume":"120","author":"Pieters","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102614_bib40","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/jth.14002","article-title":"An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH","volume":"16","author":"Pieters","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102614_bib41","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/s41598-024-52844-4","article-title":"Internal fibrinolysis of fibrin clots is driven by pore expansion","volume":"14","author":"Risman","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.rpth.2024.102614_bib42","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1111\/j.1538-7836.2009.03596.x","article-title":"Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?","volume":"7","author":"Willemse","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102614_bib43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1538-7836.2003.00028.x","article-title":"Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis","volume":"1","author":"Schneider","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102614_bib44","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3390\/biom12060807","article-title":"The applicability of current turbidimetric approaches for analyzing fibrin fibers and other filamentous networks","volume":"12","author":"Belcher","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.rpth.2024.102614_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100285","article-title":"What is the diameter of a fibrin fiber?","volume":"7","author":"Belcher","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102614_bib46","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.bpj.2010.04.059","article-title":"Nanostructure of the fibrin clot","volume":"99","author":"Yeromonahos","year":"2010","journal-title":"Biophys J"},{"key":"10.1016\/j.rpth.2024.102614_bib47","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood-2015-06-652214","article-title":"Thrombin and fibrinogen \u03b3' impact clot structure by marked effects on intrafibrillar structure and protofibril packing","volume":"127","author":"Domingues","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102614_bib48","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/biom14020230","article-title":"Comprehensive analysis of the role of fibrinogen and thrombin in clot formation and structure for plasma and purified fibrinogen","volume":"14","author":"Risman","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.rpth.2024.102614_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.transci.2007.12.005","article-title":"Thrombin generation, fibrin clot formation and hemostasis","volume":"38","author":"Wolberg","year":"2008","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.rpth.2024.102614_bib50","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1016\/j.bpj.2022.07.023","article-title":"Effects of clot contraction on clot degradation: a mathematical and experimental approach","volume":"121","author":"Risman","year":"2022","journal-title":"Biophys J"},{"key":"10.1016\/j.rpth.2024.102614_bib51","series-title":"Anticoagulation. Treasure Island, FL","author":"Umerah","year":"2024"},{"key":"10.1016\/j.rpth.2024.102614_bib52","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.rpth.2024.102614_bib53","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/1358863X231154756","article-title":"Vascular disease patient information page: a guide for patients with newly diagnosed deep vein thrombosis or pulmonary embolism","volume":"28","author":"Frank","year":"2023","journal-title":"Vasc Med"},{"key":"10.1016\/j.rpth.2024.102614_bib54","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3324\/haematol.2008.000042","article-title":"Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins","volume":"94","author":"Semeraro","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102614_bib55","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1021\/acs.jmedchem.0c02072","article-title":"Phosphinanes and azaphosphinanes as potent and selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)","volume":"64","author":"Schaffner","year":"2021","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.rpth.2024.102614_bib56","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1021\/jm0702433","article-title":"Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis","volume":"50","author":"Bunnage","year":"2007","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.rpth.2024.102614_bib57","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.V88.6.2093.bloodjournal8862093","article-title":"The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent","volume":"88","author":"Bajzar","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102614_bib58","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1074\/jbc.M205006200","article-title":"Stabilization versus inhibition of TAFIa by competitive inhibitors in\u00a0vitro","volume":"278","author":"Walker","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.rpth.2024.102614_bib59","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1538-7836.2011.04495.x","article-title":"TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation","volume":"9","author":"Hendrickx","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102614_bib60","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102614_bib61","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12885-016-2359-1","article-title":"Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis","volume":"16","author":"Bazzi","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.rpth.2024.102614_bib62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s10856-024-06775-1","article-title":"Flow affects the structural and mechanical properties of the fibrin network in plasma clots","volume":"35","author":"Eyisoylu","year":"2024","journal-title":"J\u00a0Mater Sci Mater Med"},{"key":"10.1016\/j.rpth.2024.102614_bib63","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/bloodadvances.2020002923","article-title":"Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system","volume":"4","author":"Suzuki","year":"2020","journal-title":"Blood Adv"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924003091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924003091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:51:40Z","timestamp":1778896300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924003091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2475037924003091"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102614","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dependence of clot structure and fibrinolysis on apixaban and clotting activator","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102614"}}